Alendronic acid liposomal - BIOrest

Drug Profile

Alendronic acid liposomal - BIOrest

Alternative Names: LABR-312

Latest Information Update: 02 Feb 2016

Price : $50

At a glance

  • Originator BIOrest
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Monocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery restenosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Jan 2016 BIOrest plans a phase II trial for Coronary artery restenosis in Poland, Canada and United Kingdom (NCT02645799)
  • 01 Dec 2015 BIOrest completes a phase II trial in Coronary artery restenosis in Israel (NCT00739466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top